Diabetes drug profit soaring

Despite climbing quarterly profits of 5 per cent, diabetic drug manufacturer Takeda has left its outlook unchanged due to uncertainty over their blockbuster drug Actos.
The company posted first quarter results at the same time as another Japanese drug maker, Daiichi Sankyo.
Actos is the major earner for Takeda, and as Glaxo drug Avandia has been put through the media mill, sales of actos have in fact climbed. In June, sales of Actos climbed by 40 per cent.
Takeda have held their forecast due to upcoming deliberations over the safety of Avandia and Actos.